$5.340
-0.372 (-6.97%)At close
GBIO News
GBIO Events
Satellos Bioscience Appoints Antoinette Paone as Chief Development Officer
Satellos Bioscience (MSCLF) announced the appointment of Antoinette Paone as chief development officer and head of regulatory affairs. Paone joins Satellos from Generation Bio (GBIO), where she most recently served as COO.
Wedbush Lowers Generation Bio Price Target to $5.50
Wedbush lowered the firm's price target on Generation Bio (GBIO) to $5.50 from $7 and keeps a Neutral rating on the shares. Xoma (XOMA) will acquire Generation Bio for $4.2913/share plus a non-transferable CVR, with an expected close in February 2026. The firm expects the transaction to proceed and does not anticipate other bidders. The CVR will include cash at closing in excess of $28.97M, 90%-100% of savings on Generation Bio's office lease obligations, a share of milestone and royalty payments from Moderna (MRNA), and a share of payments from out-license or sale of the ctLNP delivery platform.
Xoma to Acquire Generation Bio for $4.2913 per Share
Xoma to acquire Generation Bio for $4.2913 per share
Xoma Royalty Acquires Generation Bio at $4.2913 per Share
Xoma Royalty (XOMA) announced it has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders also will receive one non-transferable contingent value right per share that entitles holders to receive potential payments of a pro rata portion of: 100% of the amount by which net cash at closing, as finally determined pursuant to the CVR agreement, exceeds $29M; either 90% or 100% of any savings realized by Xoma Royalty on the company's Cambridge office lease obligations, subject to the timing of resolution of the lease obligations; a share of any proceeds from Generation Bio's existing license agreement with Moderna, which includes potential development and commercial milestones and royalties on commercial sales, calculated on a sliding scale delivering up to 90% of such payments to CVR holders; and a share of payments from any out license or sale of the Generation Bio ctLNP delivery platform, calculated on a sliding scale delivering up to 70% of such payments to CVR holders following the closing.Following a thorough review process conducted with the assistance of its legal and financial advisors, Generation Bio's board of directors has determined that the acquisition by Xoma Royalty is in the best interests of all Generation Bio stockholders and has unanimously approved the Merger Agreement. Generation Bio stockholders in possession of approximately 15% of Generation Bio common stock have signed support agreements under which such stockholders agreed to tender their shares in the Offer and support the merger. The acquisition is expected to close in February 2026.
Generation Bio Trading Halted, News Pending
Generation Bio trading halted, news pending
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.